Ocuphire Pharma Investor Day Presentation Deck

DR DME 32 Comparison of Subject Exposure Before and After ZETA-1 ☆ Subject-Days of Exposure at 600 mg/day Substantially Increases Exposure Data Total Subjects Subject-Days of Exposure Subjects with ≥21 days of exposure Subjects with >300 days of exposure Prior to ZETA-1 34 Subjects 2078 Subject-days 16 Subjects 3 Subjects ≥600 mg/day *Assumed 50% of ZETA-1 patients are on active treatment **Many of the subjects between 20-240 mg/day +34 +3727 +27 To Date* 68 Subjects 5805 Subject-days 43 Subjects 3 Subjects *Interim Zeta-1 Data as of 01-12-22; * Eisai and Apexian Phase 1 and Phase 2 clinical trials (subject to final safety database) <600 mg/day** Prior to ZETA-1 328 Subjects 17961 Subject-days 245 Subjects N/A Ocuphire PHARMA

View entire presentation